A Pilot Study to Assess the Combination of High-Dose Conformal Radiation Therapy (HDCRT) and Pembrolizumab in Modulating Local and Systemic T-cell Responses in Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Pembrolizumab
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics
- 01 Apr 2017 Planned primary completion date changed from 1 Jan 2021 to 1 Mar 2020.
- 27 Mar 2017 Status changed from not yet recruiting to recruiting.
- 12 Dec 2016 New trial record